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Abstract
Kupffer cells (KCs) are widely considered important contributors to liver injury during viral hepatitis due to their pro-
inflammatory activity. Herein we utilized hepatitis B virus (HBV)-replication competent transgenic mice and wild-type mice
infected with a hepatotropic adenovirus to demonstrate that KCs do not directly induce hepatocellular injury nor do they affect
the pathogenic potential of virus-specific CD8 T cells. Instead, KCs limit the severity of liver immunopathology. Mechanistically,
our results are most compatible with the hypothesis that KCs contain liver immunopathology by removing apoptotic
hepatocytesinamannerlargelydependentonscavengerreceptors.ApoptotichepatocytesnotreadilyremovedbyKCsbecome
secondarily necrotic and release high-mobility group box 1 (HMGB-1) protein, promoting organ infiltration by inflammatory
cells, particularly neutrophils. Overall, these results indicate that KCs resolve rather than worsen liver immunopathology.
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Introduction
Kupffer cells (KCs) are non-parenchymal cells that account for
approximately 15% of the total liver cell population and
constitute 80%–90% of the tissue-resident macrophages in the
whole body [1]. Due to their intravascular (sinusoidal) localiza-
tion, KCs have long been studied as scavenger cells that
physiologically remove particulate material (e.g. aged blood cells,
immune complexes and gut-derived bacterial products) from the
portal circulation [1]. In recent years KCs have been implicated
in the pathogenesis of an assortment of inflammatory liver
diseases, including viral hepatitis [2,3]. Accordingly, the current
dogma regarding the role of KCs in hepatitis B virus (HBV) or
hepatitis C virus (HCV) pathogenesis considers these cells as
important contributors to liver injury [4,5]. As the host tropism of
HBV and HCV is limited to humans and human primates [6],
this dogma has been largely inferred from mouse studies in which
KCs activated by a variety of stimuli (including the engulfment of
apoptotic hepatocytes) were shown to i) promote the intrahepatic
accumulation of pathogenic T cells and/or ii) express/produce
inflammatory mediators that are directly toxic for the hepatocyte
(e.g. tumor necrosis factor (TNF)-a, FasL, reactive oxygen
species, etc) [2,3,7]. It is worth noting, however, that most of
these studies were performed either by infecting mice with
pathogens that preferentially replicate inside KCs (e.g. cytomeg-
alovirus [8,9], influenza [10], lymphocytic choriomeningitis virus
[11], listeria [12] or leishmania [13]) or by injecting mice with
lymphocyte mitogens (such as Staphylococcus enterotoxin B and
Concanavalin A [14,15]) that cause massive intrahepatic
expansion of activated CD4 T cells. Since HBV and HCV infect
almost exclusively the hepatocyte and since liver damage during
these infections is primarily a consequence of the virus-specific
CD8 T cell response [6], we decided to assess the role of KCs in
more relevant animal models.
In one model effector HBV-specific CD8 T cells are adoptively
transferred into immunocompetent transgenic mice that replicate
HBV at high levels in the hepatocyte [16–21]. In a second model
wild-type mice previously immunized with a plasmid encoding
b-galactosidase (b-Gal) are infected with a b-Gal-expressing
hepatocyte-tropic adenovirus [21,22]. Both models revealed that
KCs have no impact on the ability of virus-specific CD8 T cells to
home to the liver, recognize antigen and kill hepatocytes, nor do
they significantly act as effector cells to destroy the hepatocytes.
Instead, KCs reduce the overall severity of T cell-mediated
immunopathology by removing apoptotic hepatocytes from the
liver.
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Treatment with clodronate liposomes (Clo-L) reduces KC
number and liver phagocytic function
HBV replication-competent transgenic mice or C57BL/6 mice
were injected intravenously with Clo-L. This treatment effectively
eliminated F4/80
+ KCs within 2 days and for at least 1 week after
injection (Figure S1 and [23,24]), without reducing the number of
liver CD11c
high dendritic cells (DCs, Figure S1) or circulating
Gr-1
high CD11b
+ polymorphonuclear neutrophils (PMNs) and
Ly-6C
+ monocytes (Figure S1). Intravenously injected fluorescent
beads failed to accumulate in the liver of Clo-L-treated mice
(not shown), while they were readily up-taken by KCs from control
animals (Figure S1). As the former mice also showed delayed
clearance of beads from the circulation (Figure S1), these results
indicate that Clo-L significantly reduced liver phagocytic function.
KC depletion exacerbates liver immunopathology in
models of acute viral hepatitis
HBV replication-competent transgenic mice were treated with
either Clo-L or saline (NaCl) 3 days prior to the transfer of effector
HBV-specific CD8 T cells. Additional groups of control mice were
injected with NaCl, liposomes containing saline (NaCl-L) or Clo-L
alone. As previously reported [17], injection of effector HBV-
specific CD8 T cells (derived from immunized syngeneic non
transgenic mice, see Methods) into saline-treated control mice
caused a transient liver disease (monitored biochemically by
measuring the serum activity of alanine aminotransferase [sALT],
an enzyme that is released into the circulation by necrotic
hepatocytes) that almost completely resolved 5 days after transfer
(Figure 1A). No difference in disease severity (monitored by sALT
activity [Figure S2] and liver histology [not shown]) was observed
when NaCl-L was injected, instead of NaCl, prior to the transfer of
effector HBV-specific CD8 T cells. As also previously reported
[17], resolution of disease in this model is due to CD8 T cell-
dependent down-regulation of viral antigens (see below and
Discussion). Surprisingly Clo-L treatment, which by itself did not
cause significant sALT elevation, markedly increased liver disease
in CD8 T cell-injected mice at all time points (Figure 1A). This
effect occurred independently of the number of effector HBV-
specific CD8 T cells that were transferred (Figure 1, B and C). To
exclude the possibility that Clo-L may prolong sALT half-life, we
injected liver extracts with a known sALT content in either control
or Clo-L-treated mice. sALT half-life in Clo-L-treated mice was
not significantly different from that of controls (489 versus 538
minutes, respectively, Figure S3), indicating that sALT is a reliable
marker of liver disease in Clo-L treated mice.
As virus-specific CD8 T cells trigger liver disease in this model,
we next asked whether KCs altered the pathogenic potential of
these cells in vivo. To this end, we first performed intravital
microscopic analysis to monitor the behavior of the transferred T
cells. Approximately 30% of visualized intrahepatic HBV-specific
CD8 T cells arrested and transiently contacted KCs (mean
interaction time of 561 second) (Video S1). Adhesion of HBV-
specific CD8 T cells to liver sinusoids did not require interaction
with KCs as the percentage of CD8 T cells stably adhering
(i.e. .30 s) to liver sinusoidal endothelial cells was similar between
saline controls and Clo-L treated mice (Figure 1D, Video S2 and
S3). The expansion and intrahepatic accumulation of the
transferred T cells (Figure 1, E and F) and the relative increase
(fold induction over mice injected with either NaCl or Clo-L alone)
of liver mRNAs encoding for IFN-c (a well-established marker of
antigen recognition by HBV-specific CD8 T cells in this model
[17,25]) (Figure 1G) or CXCL9 and CXCL10 (two IFN-c
inducible chemokines most abundantly expressed by hepatocytes
surrounding inflammatory foci [18]) (Figure 2, A and B) were also
unaffected in Clo-L treated mice. The relative increase of liver
mRNA encoding for TNF-a - another cytokine known to be
produced by activated HBV-specific CD8 T cells in this model
[17,25] and that has been proposed to promote liver damage [26]
- was reduced of about 33% and 55% at days 1 and 2, respectively,
in CD8 T cell-injected mice treated with Clo-L (Figure 2C),
indicating that KCs contributed to the production of this pro-
inflammatory soluble mediator.
As mentioned earlier, liver disease in this model is transient
because IFN-c-dependent mechanisms rapidly eliminate viral gene
products from the liver [17,25,27]. Accordingly, viral DNA, RNA
and proteins disappeared from the liver of saline- and Clo-L-
treated mice with comparable kinetics (not shown and Figure S4).
Note that 5 days after CD8 T cell injection Clo-L-treated mice
showed residual antigen reactivity in hepatocytes that appeared
morphologically damaged (Figure S4), suggesting that these target
cells were not readily removed from the liver. Importantly, the
number of infiltrating intrahepatic leukocytes (IHL), the vast
majority of which are antigen-non-specific inflammatory cells [18],
was significantly increased in CD8 T cell-injected mice that were
treated with Clo-L instead of NaCl (Figure 1H), while treatment
with Clo-L alone increased neither sALT activity (Figure 1, A, B
and C) nor IHL infiltration (Figure 1H). Together, the data
indicate that Clo-L treatment exacerbates immunopathology
independently of the number or function of intrahepatic HBV-
specific CD8 T cells and is associated with a more abundant
antigen-non-specific inflammatory cell infiltrate in the liver.
Exacerbation of liver immunopathology in face of reduced
numbers of KCs (and reduced levels of the TNF-a they produce
also indicates that KCs play little or no role as effector cells in the
destruction of hepatocytes in this system. Additionally, the
intrahepatic expression levels of potentially anti-inflammatory/
hepatoprotective cytokines such as IL-10, IL-22 or TGF-b [28–30]
were not reduced in CD8 T cell-injected Clo-L-treated mice when
compared to proper controls (Figure 2, D, E and F), indicating that
the increased liver disease observed in the former animals was not
associated to decreased production of cytoprotective factors.
Notably, intravenous Clo-L treatment is not specific for KCs,
but it apparently acts on other cell populations, particularly splenic
mononuclear phagocytes [31,32]. To rule out a contribution of
splenocytes in our system, HBV replication-competent transgenic
mice were splenectomized and treated with either Clo-L or saline
Author Summary
Kupffer cells (KCs), the resident macrophages of the liver,
are considered important contributors to liver injury
during viral hepatitis due to their pro-inflammatory
activity. Herein we utilized two different mouse models
of viral hepatitis (where liver damage is triggered, as
during viral hepatitis in humans, by virus-specific CD8 T
cells) to show that KCs do not directly induce liver injury
nor do they affect the pathogenic potential of virus-
specific CD8 T cells. Instead, KCs limit the severity of liver
immunopathology. Mechanistically, our results are most
compatible with the hypothesis that KCs contain liver
immunopathology by removing dying hepatocytes. Dying
hepatocytes not readily removed by KCs release high-
mobility group box 1 (HMGB-1) protein, promoting organ
infiltration by inflammatory cells, particularly neutrophils.
These results indicate that KCs resolve rather than worsen
liver disease.
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Splenectomized animals showed a degree of liver disease severity
that was virtually identical to that of non-splenectomized controls
(Figure 3A), strongly suggesting that the capacity of Clo-L to
exacerbate liver disease depends on depletion of KCs rather than
depletion of splenic mononuclear phagocytes. Additional evidence
supporting the notion that KC depletion is associated with liver
disease exacerbation in this model comes from experiments where
HBV replication-competent transgenic mice were administered
with gadolinium chloride (GdCl3) prior to the transfer of CD8 T
cells. GdCl3 is a rare earth metal that - like Clo-L - has been
widely used to eliminate KCs in mice [33–35]. As shown in Figure
S1 and Figure 3B, respectively, GdCl3 treatment reduced KC
number by more than 75% (without reducing the frequency of
circulating monocytes and PMNs, not shown) and caused a
significant increase in sALT activity at all time points after CD8 T
cell transfer.
Next, we extended our study to a previously established
infection model [21] in which liver immunopathology is triggered
by endogenous b-Gal-specific CD8 T cells that recognize
hepatocytes infected by a b-Gal-expressing, replication-deficient
adenovirus (Ad-b-Gal). C57BL/6 mice were immunized intra-
muscularly with a b-Gal-expressing plasmid to generate b-Gal-
specific CD8 T cells. Three weeks later the mice were grouped
based on the frequency of circulating b-Gal-specific CD8 T cells
and then infected with the hepatotropic Ad-b-Gal (10
9 pfu/
mouse) (see Methods). Clo-L treatment was carried out one day
after Ad-b-Gal infection, when the percentage of b-Gal-expressing
hepatocytes is maximal and viremia is no longer detectable ([21]
and not shown). When compared to saline-treated controls, Clo-L-
treated mice showed i) significantly higher sALT activity
(Figure 4A), ii) comparable numbers of intrahepatic b-Gal-specific
CD8 T cells (Figure 4B), iii) comparable amounts of liver IFN-c
mRNA (Figure 4C), and iv) increased organ infiltration of antigen
non-specific leukocytes (Figure 4D). Thus, KC-related pathogenic
events that are similar to those observed in HBV replication-
competent transgenic mice (Figure 1) were also operative in this
infection model of liver immunopathology.
Impaired removal of apoptotic hepatocytes and focal
hepatocellular necrosis in Clo-L- or GdCl3-treated mice
We next set out to identify the mechanism by which KCs limit
liver immunopathology. When we quantified morphometrically
the number of hepatocytes that stained positive for cleaved caspase
3 (CC3, a marker of hepatocellular apoptosis) in either HBV
replication-competent transgenic mice killed 1 day after CD8
T cell injection (Figure 5A) or C57BL/6 mice killed 3 days after
Ad-b-Gal infection (not shown), we observed a ,3-fold increase
of CC3
+ hepatocytes in Clo-L-treated mice compared with
saline-treated controls, with similar results observed in GdCl3-
treated animals (not shown). One day later, the number of
apoptotic hepatocytes increased disproportionately in Clo-L- or
GdCl3-treated mice, resulting in the formation of large necroin-
flammatory foci thzat also displayed evident focal hepatocellular
necrosis and dropout (Figure 5B and not shown). By day 5 after
CD8 T cell injection or Ad-b-Gal-infection, virtually no CC3
+
hepatocytes were visible in saline-treated control animals, while
these cells remained readily detectable in Clo-L- or GdCl3-treated
mice (Figure 5C and not shown). These results indicate that the
higher sALT levels observed in these latter animals (Figures 1, 3, 4
and S2) probably reflected the secondary necrosis of apoptotic
hepatocytes that had not been removed due to the absence of KCs
and, therefore, accumulated over time. That these higher sALT
levels did not reflect the destruction of greater numbers of
hepatocytes by the CD8 T cells was further suggested by the serum
levels of albumin and bilirubin (two indicators of metabolic
functions arising from healthy hepatocytes), which were virtually
identical in the saline- and Clo-L-treated mice (Figure S5).
HMGB-1 and the role of PMNs
Cytometric analyses of the liver infiltrate in the mice described
in Figures 1 and 4 revealed that the number of intrahepatic PMNs,
a prominent intrahepatic inflammatory cell subset, was signifi-
cantly higher in Clo-L-treated animals both in terms of relative
frequency (Figure 6A and not shown) and, more importantly,
absolute numbers (Figure 6B and not shown). The frequency/
number of other abundant intrahepatic subsets such as CD8+ T
cells (both antigen-specific and antigen-non-specific) and
CD11c
high DCs (peak values of 9%/2.3610
6 and 4.7%/1.2610
6
respectively) did not change as a function of Clo-L treatment
(not shown). Since HMGB-1 translocation in damaged hepato-
cytes has been previously linked to liver PMN recruitment in this
model [36], we next monitored HMGB-1 expression in the above-
mentioned livers. Large numbers of cytoplasmic HMGB-1
+
hepatocytes juxtaposed to or surrounded by PMNs were found
in the livers of Clo-L-treated HBV replication-competent
transgenic mice injected with CD8 T cells (Figure 6C). Note that
nucleo-cytoplasmic translocation of HMGB-1 often reflects its
release by necrotic, as opposed to apoptotic, cells [37]. The
increased PMN recruitment in Clo-L treated mice occurred in face
of intrahepatic CXCL1 and IL-17 (known PMN chemoattractants
[38,39]) expression levels that were comparable to those detected
in control mice (Figure 2, G and H), which showed fewer
cytoplasmic HMGB-1
+ hepatocytes and fewer infiltrating PMNs
(Figure 6C). Similar results were obtained in mice infected with
Ad-b-Gal (not shown). Thus, impaired removal of apoptotic
hepatocytes by KCs promoted accumulation of cytoplasmic
HMGB-1
+ hepatocytes and intrahepatic PMN infiltration.
Figure 1. KCs limit liver immunopathology in HBV replication-competent transgenic mice, without affecting the number or
function of virus-specific effector CD8 T cells (CTL). (A, B and C) Mean sALT activity (units/liter) measured at the indicated time points after
intravenous injection of 10
7 (A), 5610
7 (B) or 0.5610
7 (C) HBV-specific effector CD8 T cells (CTL) in HBV replication-competent transgenic mice that
received the indicated treatment. n=6. (D) Sticking fraction (the percentage of cells that arrested for $30 s in the total flux) of HBV-specific CTL in
liver sinusoids of control (white) or Clo-L-treated (black) HBV replication-competent transgenic mice. n=3. (E) Mean fluorescent intensity of CFSE-
labeled HBV-specific CTL recovered from control (white) or Clo-L-treated (black) HBV replication-competent transgenic livers, two days after
intravenous injection of 10
7 HBV-specific CTL. n=6. (F) Absolute number of HBV-specific CTL recovered from control (white) or Clo-L-treated (black)
HBV replication-competent transgenic livers, at the indicated time points after intravenous injection of 10
7 HBV-specific CTL. n=6. (G) IFN-c mRNA
expression in control (white) or Clo-L-treated (black) HBV replication-competent transgenic livers, at the indicated time points after intravenous
injection of 10
7 HBV-specific CTL. Results are expressed as fold induction (f.i.) over controls (i.e. mice injected with either NaCl or Clo-L alone), after
normalization for the housekeeping gene L32. n=6. (H) Absolute number of intrahepatic leukocytes (IHL) recovered from control (white) or Clo-L-
treated (black) HBV replication-competent transgenic livers, at the indicated time points after intravenous injection of 10
7 HBV-specific CTL. n=6.
All data are expressed as mean 6 standard deviation and are representative of at least 3 independent experiments that gave similar results;
differences between CTL-injected mice treated or not with Clo-L were not statistically significant unless otherwise indicated, * p,0.05, ** p,0.001.
doi:10.1371/journal.ppat.1002061.g001
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apoptotic hepatocytes from Clo-L-treated mice, as their depletion
by anti-Gr-1 antibodies (Figure S6) was associated with detec-
tion of higher numbers of cytoplasmic HMGB-1
+ hepatocytes
(not shown) and higher sALT values (Figure 6D). Higher numbers
of cytoplasmic HMGB-1
+ hepatocytes (not shown), higher sALT
values (Figure 6E) and reduced numbers of liver infiltrating
PMNs (Figure S6) were also detected in Clo-L-treated HBV
Figure 2. Clo-L treatment does not affect the hepatic gene expression of CXCL9, CXCL10, IL-10, IL-22, TGF-b, CXCL1 or IL-17 but
reduces that of TNF-a. CXCL9 (A), CXCL10 (B), TNF-a (C), IL-10 (D), IL-22 (E), TGF-b (F), CXCL1 (G) or IL-17 (H) liver mRNA expression from mice
described in the legend to Figure 1G. Results are expressed as fold induction (f.i.) over controls (i.e. mice injected with either NaCl or Clo-L alone), after
normalization for the housekeeping gene L32. n=6. Differences were not statistically significant unless otherwise indicated, * p,0.05.
doi:10.1371/journal.ppat.1002061.g002
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with a blocking monoclonal Ab specific for mouse HMGB-1
(Figure S6) - prior to CD8 T cell transfer. Along with the finding
that, when compared to controls, serum HMGB-1 levels were
increased in Clo-L-treated mice that were injected with CD8 T
cells or infected with Ad-b-Gal (not shown), these results reiterate
the notion that the release of HMGB-1 from secondarily necrotic
hepatocytes most likely contributed to recruit PMNs into the liver.
Since PMN depletion and HMGB-1 neutralization prolonged
disease severity in these animals only partially, we reasoned that,
under the inflammatory conditions generated by CD8 T cells, the
depleting effect of a single Clo-L administration (given 3 days prior
to transfer) probably persisted less than one week (which is the time
frame we and others have observed in un-manipulated mice, not
shown and [24]). Indeed, F4/80
+ KCs (likely derived from
hematogenous monocyte precursors [40]) re-appeared in the liver
3 days after CD8 T cell transfer (Figure 7A), and a second
injection of Clo-L at this time extended the local persistence of
apoptotic and cytoplasmic HMGB-1
+ hepatocytes (not shown) and
the relative increase in sALT activity (Figure 7B) by about a week
when compared to mice receiving a single dose of Clo-L
(Figure 1A). Worsening of liver disease severity (and even mortality
in the case of Clo-L treated mice) (Figure S7) was also observed in
HBV replication-competent transgenic mice in which all WBC
(including PMNs and monocytes) were completely eliminated by
whole-body irradiation prior to CD8 T cell transfer (Figure S7),
reiterating the notion that compensatory functions mediated by
liver infiltrating phagocytic cells help KCs at containing liver
immunopathology.
The role of scavenger receptors
Although the administration of Clo-L- or GdCl3 in CD8 T cell-
injected/Ad-b-Gal infected mice did not increase the liver
expression of potentially hepatotoxic factors (e.g. IFN-c, TNF-a
or IL-17), it is formally possible that these treatments might have
resulted in the release of undetermined cytotoxic factors
exacerbating liver damage. To confirm that KCs contain liver
immunopathology independently of Clo-L- or GdCl3 treatments
and to provide mechanistic insight on how KCs phagocytose
apoptotic hepatocytes, we made use of Polyinosinic acid (Poly(I)),
a ligand for most macrophage scavenger receptors and a known
blocker of KC phagocytosis [41–43]. Polyuridylic acid (Poly(U)),
a non-scavenger receptor ligand, was used as control [41–43]. Of
note, KCs isolated from the liver of HBV replication-competent or
C57BL/6 mice were found to express macrophage scavenger
receptor 1 (MSR-1) and scavenger receptor class b1 (Scarb-1)
(Figure S8 and not shown), two prototypic class A and class B
scavenger receptors, respectively, which can be bound by Poly(I)
[41–43]. Neither Poly(I)- nor Poly(U)-treatment reduced the
number of F4/80
+ KCs (Figure S8) or the intrahepatic number
of innate immune cells such as CD11c
high DCs, NK1.1
+ CD3
- NK
cells and NK1.1
+ CD3
+ NKT cells (Figure S8). Further, both of
these treatments failed to reduce the number of circulating
Gr-1
high CD11b
+ PMNs (not shown). When compared to mice
treated with Poly(U), however, mice treated with Poly(I) exhibited
delayed removal of fluorescent microbeads from the circulation
(Figure S8), providing evidence for the efficacy of this latter
compound at inhibiting liver phagocytosis.
Importantly, HBV replication-competent transgenic mice and
C57BL/6 mice that we treated with Poly(I) either 5 minutes before
CD8 T cell transfer or 3 days after Ad-b-Gal infection (more than
2 days following maximal hepatocellular infection) displayed (at
peak disease severity) higher sALT values than Poly(U)-treated
controls (Figure 8A) and this was associated with i) similar numbers
of intrahepatic virus-specific CD8 T cells (Figure 8B), ii) similar
amounts of liver IFN-c mRNA (Figure 8C), iii) increased
accumulation of apoptotic (Figure 8D) and necrotic hepatocytes
(not shown) and iv) increased infiltration of antigen non-specific
leukocytes (Figure 8E). Together, our results, based on mechanis-
tically distinct approaches, indicate that CD8 T cell-induced liver
immunopathology can be worsened by depleting KCs or by
inhibiting their scavenger receptor-dependent capacity to phago-
cytose apoptotic hepatocytes.
Discussion
We show here that KCs play a previously unappreciated role in
the pathogenesis of viral hepatitis, i.e. they contribute to the
resolution of liver pathology induced by virus-specific effector CD8
T cells. We initially found that the injection of Clo-L (a treatment
widely used to deplete murine KCs [23,24]) was associated with a
highly significant 2–3 fold increase in sALT activity (a commonly
used marker of liver cell injury) at all time points measured. This
was an unexpected finding since KCs are currently regarded as
contributors to liver damage during viral hepatitis. Also unex-
pectedly we found that the overall number and function of
intrahepatic virus-specific CD8 T cells - two factors directly linked
to liver disease severity - were unaffected in these animals. Indeed,
none of the various steps leading to hepatocellular destruction by
Figure 3. The effects of splenectomy and GdCl3 on liver
disease severity. (A–B) Mean sALT activity (units/liter) measured at
the indicated time points after intravenous injection of 10
7 HBV-specific
effector CD8 T cells (CTL) that received the indicated treatment. n=6.
All data are expressed as mean 6 standard deviation and are
representative of at least 2 independent experiments that gave similar
results; note that no difference in sALT activity was detected between
splenectomized and non-splenectomized animals at all time points
after CTL injection; differences between CTL-injected mice treated or
not with Clo-L or GdCl3 were not statistically significant unless
otherwise indicated, ** p,0.001.
doi:10.1371/journal.ppat.1002061.g003
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adhesive behavior of CD8 T cells to the liver microvasculature was
shown to be normal, despite the fact that transient CD8 T cell/
KC interactions often took place in the sinusoids of control mice.
Clo-L treatment did not impinge on the capacity of CD8 T cells to
recognize hepatocellular antigens either, as these cells produced
IFN-c (a cytokine that in our systems is exclusively expressed by in
vivo activated virus-specific CD8 T cells [25]), divided and
accumulated intrahepatically at control levels. Along with the
notions that treatment with Clo-L alone did not induce liver
inflammation and that the GdCl3-dependent depletion of KCs
reproduced the CD8 T cell-dependent disease exacerbation
observed after Clo-L treatment, these initial results indicated that
KCs were not contributing to liver injury, either as effector cells
directly involved in the destruction of hepatocytes, or as promoters
of CD8 T cell-induced pathology.
The results also raised the question of how sALT levels in KC-
depleted animals increased disproportionally when compared to
the number or function of virus-specific effector CD8 T cells.
Pertinent to this question it is worth mentioning that virus-specific
effector CD8 T cells kill hepatocytes by apoptosis [44,45].
Apoptotic hepatocytes preserve cell membrane integrity [46]
and, as such, they do not release their cytosolic ALT content into
the circulation. Accordingly, only necrotic hepatocytes should
Figure 4. KCs limit liver immunopathology in adenovirus-infected mice, without affecting the number or function of virus-specific
CTL. (A) Mean sALT activity (units/liter) measured at the indicated time points after infection with 10
9 pfu of a b-Gal-expressing adenovirus
(Ad-b-Gal)in mice that received theindicatedtreatment. n=6.(B)Absolutenumberof b-Gal-specific CTLrecoveredfrom control (white) or Clo-L-treated
(black) livers, at the indicated time points after infection with 10
9 pfu of Ad-b-Gal. n=6. (C) IFN-c mRNA expression in control (white) or Clo-L-treated
(black) livers, at the indicated time points after infection with 10
9 pfu of Ad-b-Gal. Results are expressed as fold induction (f.i.) over controls (i.e. mice
injected with either NaCl or Clo-L alone), after normalization for the house-keeping gene L32. n=6. (D) Absolute number of intrahepatic leukocytes (IHL)
recovered from control (white) or Clo-L-treated (black) livers, at the indicated time points after infection with 10
9 pfu of Ad-b-Gal. n=6. All data are
expressedas mean6 standarddeviationandarerepresentativeof atleast3 independentexperiments thatgave similarresults; differences betweenAd-
b-Gal-infected mice treated or not with Clo-L were not statistically significant unless otherwise indicated, * p,0.05, ** p,0.001.
doi:10.1371/journal.ppat.1002061.g004
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[47], we hypothesized that i) KC depletion resulted in the
accumulation of apoptotic hepatocytes in situ, and that ii) these
apoptotic cells secondarily evolved into ALT-releasing necrotic
hepatocytes since they were not readily removed by KCs.
Evidence supporting these hypotheses emerged from experiments
where the administration of an inhibitor of KC phagocytosis that
does not deplete macrophages also promoted high sALT levels,
control-level intrahepatic numbers of pathogenic virus-specific
CD8 T cells and, most relevantly, liver accumulation of apoptotic
Figure 5. Impaired removal of apoptotic hepatocytes and focal hepatocellular necrosis in Clo-L-treated mice. (A,C) Representative
immunohistochemical micrographs of control (left panels) or Clo-L-treated (right panels) HBV replication-competent transgenic livers, one (A) or five
(C)daysafterintravenousinjection of10
7 HBV-specific CTL.Cleavedcaspase3 (CC3)staininginbrown.Thenumber(mean6standarddeviation)ofCC3
+
hepatocytes was calculated in 100 high power fields (corresponding to about 4 mm
2 of liver tissue) and is indicated in bottom right insets.
N.D.: non detectable. Scale bars represent 150 mm or, in the case of the upper left inset, 20 mm. n=6, p,0.05. (B) Representative micrographs of
hematoxylin/eosin-stained control (left) or Clo-L-treated (right) HBV replication-competent transgenic livers, two days after intravenous injection of 10
7
HBV-specific CTL. Broken line delineates necroinflammatory foci. Data are representative of at least 3 independent experiments that gave similar results.
doi:10.1371/journal.ppat.1002061.g005
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PLoS Pathogens | www.plospathogens.org 8 June 2011 | Volume 7 | Issue 6 | e1002061Figure 6. HMGB-1 and the role of PMNs. (A,B) Relative frequency (A) and absolute number (B) of Gr-1
high CD11b
+ neutrophils (PMNs) recovered
from the livers of mice that received the indicated treatment, 2 days (A) or at the indicated time point (B) after intravenous injection of 10
7
HBV-specific CTL. (C) Representative immunohistochemical micrographs of control (left) or Clo-L-treated (right) HBV transgenic livers, two days after
intravenous injection of 10
7 HBV-specific CTL. HMGB-1 staining in brown. Note the nuclear-to-cytoplasm translocation of HMGB-1 in hepatocytes
surrounded by PMNs (arrowhead). Scale bar represents 150 mm. n=3 (D and E) Mean sALT activity (units/liter) measured at the indicated time points
after intravenous injection of 10
7 HBV-specific CTL in HBV transgenic mice that received the indicated treatment. Irr, irrelevant antibodies. n=6.
All data are expressed as mean 6 standard deviation and are representative of at least 3 independent experiments that gave similar results;
Kupffer Cells Resolve Liver Immunopathology
PLoS Pathogens | www.plospathogens.org 9 June 2011 | Volume 7 | Issue 6 | e1002061and necrotic hepatocytes. Notably, these experiments also
identified scavenger receptors as mediators of KC-dependent
phagocytosis of apoptotic hepatocytes during viral hepatitis.
Additional evidence supporting the hypotheses emerged from
histological analysis demonstrating progressive accumulation of
hepatocellular apoptosis, hepatocellular necrosis and dropout in
the liver of animals in which KCs were either reduced in their
number or inhibited in their phagocytic function. These
pathological signs were also accompanied by the detection of
large numbers of hepatocytes displaying nucleo-cytoplasmic
translocation of HMGB-1.
As nucleo-cytoplasmic translocation of HMGB-1 frequently
reflects the release of this ‘‘danger signal’’ from necrotic cells
[48] and as HMGB-1 release is known to trigger PMN liver
recruitment [36], it was not surprising that PMNs were abundantly
found in the liver of mice where KCs were numerically reduced or
functionally inhibited. The fact that reduced PMN liver infiltration
(mediated by either PMN depletion or HMGB-1 neutralization)
worsened hepatic inflammation even further supports the concept
that PMNs performed compensatory phagocytic functions in these
livers. This is an interesting observation since PMNs have been
previously reported to contribute to CD8 T-cell induced organ
damage by facilitating the intrahepatic homing of antigen non-
specific mononuclear cells [19,20]. Thus, it would appear that
HMGB-1-responding PMNs can exert more than just a detri-
mental role, since - like KCs - they have the potential to remove
apoptotic hepatocytes and ameliorate liver immunopathology. It is
relevant to point out, however, that this beneficial anti-
inflammatory role of PMNs becomes apparent only under
conditions of reduced KC function.
It is also relevant to point out that the experimental approaches
we used to deplete KCs (intravenous injection of Clo-L or GdCl3)
or to inhibit their function (intravenous injection of Poly(I)) are not
exclusively specific for KCs (although they did not alter the
frequency of circulating monocytes and PMNs). Indeed, these
approaches have been shown to moderately impact other
macrophage populations, particularly those (e.g. splenic mononu-
clear phagocytes) that - like KCs - are not separated from the
bloodstream by an endothelial barrier [31,32,49]. Experiments
utilizing splenectomized mice ruled out the possibility that splenic
mononuclear phagocytes are involved in the exacerbation of liver
disease severity observed in KC-depleted animals.
Of note, hepatic inflammation triggered by virus-specific
effector CD8 T cells eventually subsided in mice treated with
Clo-L, GdCl3 or Poly(I). This in part relates to the fact that viral
antigens were rapidly eliminated from these livers, putting an early
end to the CD8 T cell-induced pathology. Indeed, either HBV- or
Ad-b-Gal-derived hepatocellular antigens disappeared within 2–3
days after peak disease severity [21] and remained down regulated
for at least 4 weeks after transfer (in the case of HBV replication-
competent transgenic mice), or they never returned (in the case of
mice infected with the replication-deficient adenovirus)
(not shown). Although significantly prolonged in its severity,
hepatic inflammation eventually subsided even in animals
subjected to multiple administrations of Clo-L (and multiple
administrations of Poly(I), not shown). This reiterates the notion
that compensatory phagocytic functions (likely mediated by PMNs
and infiltrating monocytes with KC-precursor capacity) were
operative under these conditions. Experiments utilizing mice in
which all circulating WBC (including PMNs and monocytes) are
permanently eliminated through whole-body irradiation further
supported the ‘‘compensatory’’ concept. Predictably, restoration
of anatomical integrity was accompanied by hepatocellular
differences between CTL-injected mice treated or not with Clo-L (A,B) or between Clo-L- and CTL-injected mice treated or not with aGr-1 antibodies
(E) were not statistically significant unless otherwise indicated, * p,0.05, ** p,0.001.*
doi:10.1371/journal.ppat.1002061.g006
Figure 7. Recruitment of F4/80
+ cells into the inflamed liver
and prolongation of disease severity in CTL-injected mice
receiving a second Clo-L injection. (A) Representative confocal
micrographs of livers from NaCl- (left panels) or Clo-L-treated
(right panels) HBV replication-competent transgenic mice one or three
days after intravenous injection of 10
7 HBV-specific CTL. Anti-F4/80
staining in red, TO-PRO-3 (TP3) staining of nuclei in blue. Scale bar
represents 150 mm. n=3. (B) Mean sALT activity (units/liter) measured at
the indicated time points after intravenous injection of 10
7 HBV-specific
CTL in HBV replication-competent transgenic mice that received the
indicated treatment. Clo-L was injected 3 days before and 3 days after
CTL injection. n=6. All data are expressed as mean 6 standard
deviation and are representative of at least 3 independent experiments
that gave similar results; differences between CTL-injected mice treated
(twice) or not with Clo-L were not statistically significant unless
otherwise indicated, * p,0.05, ** p,0.001.
doi:10.1371/journal.ppat.1002061.g007
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number of proliferating cell nuclear antigen [PCNA]- or Ki67-
positive hepatocytes), which remained detectable until liver
inflammation was completely resolved (not shown).
The results herein described contradict the current dogma that
views KCs as solely pro-inflammatory cells during viral hepatitis.
Indeed, the results indicate that, while KCs exhibit pro-
inflammatory activities (such as the production of TNF-a), their
overall net effect is anti-inflammatory. Our experiments were
performed in animal models in which - as it occurs during HBV or
HCV infection - virus-specific effector CD8 T cells that recognize
hepatocellular antigens trigger viral hepatitis. While relevant to
study the effector phase of liver immunopathology, our models
were not designed to evaluate a possible role for KCs in the
priming of virus-specific T cell responses. Future work will address
this issue.
In conclusion, we found that KCs limit the severity of CD8 T
cell-induced liver pathology in mouse models of viral hepatitis.
Mechanistically, our data indicate that KCs limit liver immuno-
pathology affecting neither the accumulation nor the function of
intrahepatic virus-specific effector CD8 T cells with pathogenic
potential. Rather, our results are most compatible with the
hypothesis that KCs hasten resolution of liver immunopathology
by removing apoptotic hepatocytes that are killed by effector CD8
T cells (see also the schematic representation depicted in Figure 9).
Failure to do so results in the secondary necrosis of hepatocytes
Figure 9. Schematic representation of the mechanisms whereby KCs contain CTL-induced liver pathology. Following antigen
recognition virus-specific CTL trigger hepatocyte apoptosis. KCs readily remove apoptotic hepatocytes, thus limiting the release of HMGB-1 protein
by secondary necrotic cells. HMGB-1 release promotes organ infiltration of inflammatory cells, particularly PMNs.
doi:10.1371/journal.ppat.1002061.g009
Figure 8. KCs remove apoptotic hepatocytes in a scavenger receptor-dependent manner. HBV replication-competent transgenic
(left column) or wild-type (right column) mice were treated with the scavenger receptor inhibitor Poly(I) or its control Poly(U) prior to HBV-specific
CTL transfer (in the case of HBV transgenic mice) or one day after Ad-b-Gal infection (for wild-type mice). All the analyses were performed at the peak
of liver disease (two days after HBV-specific CTL transfer or four days after Ad-b-Gal infection. n=6. (A) Mean sALT activity (units/liter); (B) absolute
number of intrahepatic HBV-specific (left) or Ad-b-Gal-specific (right) CTL; (C) intrahepatic IFN-c mRNA expression (assessed as in Figure 1G);
(D) number of CC3
+ hepatocytes (assessed as in Figure 4A and C) and (E) number of total intrahepatic leukocytes (IHL). All data are expressed as mean
6 standard deviation and are representative of at least 3 independent experiments that gave similar results. Differences between Poly(I)- or Poly(U)-
treated mice were not statistically significant unless otherwise indicated.
doi:10.1371/journal.ppat.1002061.g008
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humans during HBV and HCV infections, where CD8 T cell-
dependent pathogenic mechanisms similar to those described
herein are operative.
Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. These
studies were approved by the Animal Review Board of the San
Raffaele Scientific Institute (Permit Number 390) and by the
Institutional Animal Committee of The Scripps Research Institute
(Permit Number 09-0124). All surgery was performed with mice
kept anesthetized by continuous administration of 2% isoflurane in
2 L/minute oxygen through a nose cone and all efforts were made
to minimize suffering.
Mice
HBV replication-competent transgenic mouse (lineage 1.3.32)
have been previously described [16]. Lineage 1.3.32 (inbred
C57BL/6, H-2
b) was crossed with B10.D2 mice (H-2
d) to produce
H-2
bxd F1 hybrids prior to injection of H-2
d-restricted hepatitis B
surface antigen (HBsAg)-specific CD8 T cell lines. C57BL/6 and
B6.PL-Thy1a/CyJ (Thy-1.1) mice were purchased from The
Scripps Research Institute breeding colony or from Charles River
Laboratories (Calco, Italy). Bone marrow chimeric phosphoglyc-
erate kinase (PGK)-GFP mice replicating HBV were created by
transplanting BM cells derived from PGK-GFP (H-2
bxd F1
hybrids, a kind gift of Michele De Palma, San Raffaele Scientific
Institute, Milan, Italy) into irradiated 1.3.32 HBV mice. Thy-1.1
mice were crossed once with B10.D2 mice prior to immunization
with plasmid DNA- and vaccinia virus-encoding HBsAg as
previously described [21]. In some experiments, mice were
subjected to whole-body irradiation or splenectomy, as described
[50,51]. In all experiments mice were matched for age (8 weeks),
sex (males) and, in case of lineage 1.3.32, for serum hepatitis B e
antigen (HBeAg) levels before experimental manipulation. All
animals were housed in pathogen-free rooms under strict barrier
conditions.
Injection of HBV-specific CD8 T cell lines
HBV-specific CD8 T cell lines were derived from spleen cells of
immunized nontransgenic Thy-1.1 x B10.D2 male mice as
described [21]. After 3 weeks of in vitro stimulation, the cells were
tested for antigen specificity by flow cytometry as described
[18,21]. CD8
+ cells that were over 95% specific for the
immunodominant peptide epitope Env 28–39 of HBsAg [44]
were injected intravenously at different doses (0.5610
7 cells/
mouse, 1610
7 cells/mouse or 5610
7 cells/mouse) into 1.3.32
mice. One, 2, 3, 5, 7 or 14 days later mice were killed and their
livers were perfused and harvested for histological and flow
cytometry analyses, or they were snap frozen in liquid nitrogen
and stored at -80uC for subsequent molecular analyses (see below).
b-Gal DNA immunization and adenovirus infection
Fifty micrograms of a plasmid expressing b-Gal under the control
of the human CMV enhancer/promoter were injected into
regenerating tibialis anterior muscles of C57BL/6 mice 5 days after
injection of cardiotoxin as described [21]. Three weeks later mice
were grouped based on the frequency of circulating CD8
+/b-Gal96
+
T cells (between 0.2% and 0.3% of the total white blood cells) and
infected with a single intravenous dose (1610
9 pfu/mouse) of a
b-Gal-expressing adenovirus vector (Ad-b-Gal) as described [21].
Mice were killed 1, 3, 4, 5 and 7 days after infection and their livers
were processed as described above. The immunization strategy
abovementioned allowed us to focus our attention on CD8 T cell
effector functions that are independent of priming, and to
quantitatively measure the b-Gal-specific CD8 T cell response.
Indeed, under these conditions mice develop a severe liver injury
that is entirely mediated by an effector memory CD8 T cell response
specific for a single H2
b-restricted immunodominant epitope
(b-Gal96) contained within b-Gal. The response precedes any other
adenovirus-specific CTL response [21].
Depletion of KCs and PMNs
KC depletion was achieved by intravenous injection of 200 mlo f
clodronate-containing liposomes (Clo-L, a gift of Roche Diagnos-
tics GmbH, Mannheim, Germany) 3 days before CD8 T cell
transfer or one day after Ad-b-Gal infection. In some experiments
saline-containing liposomes (NaCl-L) were used as control. In
other experiments KCs were depleted by the intravenous injection
of 50 mg of gadolinium chloride (GdCl3) 24 hours and 30 minutes
before CD8 T cell transfer. In selected experiments a second Clo-
L injection was administered into 1.3.32 mice 3 days after CD8 T
cell transfer. PMN depletion was achieved by intravenous injection
of 100 mg of a rat IgG2b monoclonal antibody specific for mouse
Gr-1 (Ly-6G/Ly-6C, clone RB6-8C5; BD PharMingen) on days 1,
2 and 3 after CD8 T cell transfer as described [19]. Control mice
received an equal volume of a rat IgG2b irrelevant (Irr) Abs (clone
A95-1; BD PharMingen) at the same time points. Although clone
RB6-8C5 has been shown to deplete subsets of dendritic cells and
monocytes [52,53], it has no effect on KCs. Indeed, we detected
comparable numbers of liver F4-80
+ cells in mice injected with
either RB6-8C5 or the IgG2b control (not shown).
Generation, characterization and in vivo administration
of a-HMGB-1 Ab (DPH1.1 Ab)
The mouse monoclonal IgG1 DPH1.1 Ab specific for mouse
HMGB-1 was generated by injecting C57BL/6 mice at two-week
intervals with four doses (50 mg/mouse) of the 17-mer peptide P1
(KGKPDAAKKGVVKAEKS) derived from HMGB-1. Hybrid-
omas were generated from splenocytes by standard techniques and
tested by ELISA against the immunogen. Specificity of DPH1.1
Ab was monitored by both Western blot and immunofluorescence
as shown in Figure S4. Briefly, 500 ng or 100 ng of recombinant
HMGB-1 and the (negative control) recombinant Box-A fragment
of HMGB-1 (HMGBiotech, Milan, Italy) were separated by gel
electrophoresis and transferred onto membranes as described [48].
DPH1.1 Ab, anti-Box-A Ab (HMGBiotech, Milan, Italy) and goat
anti-mouse IgG1 Ab (BD PharMingen) were applied at 1 mg/ml
dilution. Immunofluorescence was performed as described [48] on
mouse embryonic fibroblasts (MEFs) derived from either wild type
mice or HMGB-1
2/2 mice. DPH1.1 Ab and AlexaFluor 633-
labelled goat anti-mouse IgG1 Ab (BD PharMingen) were applied
at a 50-mg/ml dilution. The in vitro activity of DPH1.1 Ab was
monitored in trans-well migration assays as basically described
[54] and shown in Figure S4. Briefly, 3T3 cells were assessed for
their migration ability by a modified Boyden chamber assay.
Recombinant HMGB-1 was added to the lower chamber at the
concentration of 30 ng/ml. Increasing concentrations of DPH1.1.
Ab were added to fifty thousand 3T3 cells seeded in the upper
chamber. Boyden chambers were incubated at 37uCi n5 %C O 2
for 3 hours. Cells remaining on the upper section of the filters were
removed mechanically. Cells that migrated to the lower section of
the filters were fixed with ethanol, stained with Giemsa (Sigma-
Aldrich), and counted in 10 random fields/filter. Each assay was
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independently. In vivo, DPH1.1. Ab was administered intrave-
nously (220 mg/mouse) 3 hours before CD8 T cell transfer.
Control mice received an equal amount of a mouse IgG1 control
Abs (BD PharMingen) at the same time point.
Analysis of KC phagocytic functions
Clo-L- or Poly(I)-treated mice were intravenously injected with
5610
8 rhodamine beads of 4 mm in diameter (provided by Z. M.
Ruggeri, The Scripps Research Institute, La Jolla, CA). Immedi-
ately after injection and 2, 4, 6, 10, 15, 20, 25 and 30 minutes later
mice were bled and the number of beads in blood samples was
assessed by flow cytometry. Livers from selected mice were
processed by confocal microscopy as described below.
Liver intravital microscopy
PGK-GFP-1.3.32 BM chimeras and 1.3.32 mice treated or not
with Clo-L were kept anesthetized by continuous administration of
2% isoflurane (Abbott S.r.l, Aprilia, Italy) in 2 L/minute oxygen
through a nose cone. After the insertion of a tail vein polyethylene
catheter attached to a syringe-pump able to deliver continuous
infusion of a 37uC saline solution (0.25 ml/hr), mice underwent
surgery. After opening the skin with a midline incision and
detaching peritoneal adherences, midline and left subcostal
incisions were made in the peritoneum through a high-
temperature cautery. The left liver lobe was exteriorized and
placed within a U-shaped, water-holding, silicon chamber placed
on an adjustable thin base. The chamber was then covered with a
cover slip at the bottom of which the left liver lobe gently flattened.
The stage was then moved to a heated microscope stage of an up-
right Axiotech Vario microscope equipped with a Colibri system
of high-performance Light Emitting Diodes (LEDs) that are fully
integrated/automated by AxioVision system software (Carl Zeiss,
Go ¨ttingen, Germany), allowing high contrast images with
simultaneous 3 color-imaging in real time. HBV-specific effector
CD8 T cells were fluorescently labeled with either CFSE (20 mM
for 7 minutes at room temperature) or Hoechst 33342 (2 mg/ml
for 15 minutes at 37uC; Invitrogen, Carlsbad, CA). Importantly,
CFSE- or Hoechst-labeled HBV-specific CD8 T cells caused the
same sALT elevation as unlabeled cells upon in vivo transfer
(not shown). Control effector CD8 T cells (specific for the
lymphocytic choriomeningitis virus, LCMV) were derived from
the spleen of mice (C57BL/66B10 D2 F1) that resolved an acute
LCMV infection and were in vitro stimulated as described [55].
Labeled CD8 T cells (1 or 560
7 cells/mouse) were transferred into
mice through the tail vein catheter and parameters of cell motility
and adhesion to liver vasculature were recorded with a AxioCam
HSC color videocamera (Carl Zeiss, Go ¨ttingen, Germany) at an
acquisition rate of 15 frames/second. The sticking fraction of
HBV-specific CD8 T cells was defined as the percentage of total
cells that became firmly adherent for $30 s while passing a liver
sinusoid within a 30 minutes observation period, as described [56].
Injection of liver extracts, Poly(I) and Poly(U)
Liver extracts containing ,6000 U of ALT were prepared as
previously described [17] and injected into 1.3.32 mice. Poly(I) and
its control Poly(U) were injected intravenously (200 mg/mouse,
Sigma) into 1.3.32 mice or C57BL/6 mice 5 minutes before CD8 T
cell transfer or 3 days after Ad-b-Gal infection, respectively.
Analyses of intrahepatic cell subsets
Intrahepatic leukocyte (IHL) isolation was performed as
described [20,21]. Cells were surface-stained with phycoerythrin
(PE)-conjugated anti-CD4 (clone RM4-5; BD Pharmingen) and
anti-CD11c (clone HL3; BD Pharmingen); Pacific Blue-conjugat-
ed anti-CD8 (clone 53-6.7; BD Pharmingen) and anti-CD3 (clone
145-2c11; BD Pharmingen); PE-Cy7-conjugated anti-CD11b
(clone M1/70; BD Pharmingen); allophycocyanin (APC)-conju-
gated anti-TCR (clone H57-597; BD Pharmingen) and anti-Ly6G
(clone 1A8; BD Pharmingen); fluorescein isothiocyanate (FITC)-
conjugated anti-Gr-1 (clone RB6-8C5; BD Pharmingen). HBV-
specific CD8 T cells were quantified by staining IHL with
PE-conjugated anti-Thy1.1 (clone OX7; BD Pharmingen) and
APC-conjugated anti-TCR (clone H57-597; BD Pharmingen) as
described [20,21]. Ad-b-Gal-specific CD8 T cells were quan-
ftified from PBMC or IHL by intracellular IFN-c staining using a
recombinant soluble dimeric H-2K
b:Ig Fusion Protein
(BD Pharmingen) complexed with the b-Gal96 immunodominant
peptide as described [21]. Liver non-parenchymal cells enriched of
KCs were isolated as previously described [57].
DNA and RNA analyses
Total DNA and RNA were isolated from blood or frozen livers
(left lobe) for analyses by Southern blot, Northern blot, RNAse
protection (RPA) and real-time PCR as previously described
[17,55]. Nylon membranes were analyzed for HBV DNA, b-Gal
DNA and RNA, and glyceraldehydes-3-phosphate dehydrogenase
(GAPDH) RNA as previously described [25]. Analysis of cytokine,
chemokine and scavenger receptors mRNAs was performed by
RPA or TaqMan Gene expression Assay (Applied Biosystems) as
previously described [17,19,20]. Real-time PCR for Ad-b-Gal was
performed as described [21].
Liver disease
The extent of hepatocellular injury was monitored by histological
analysis and by measuring sALT activity as described [17].
Quantitative morphometry was carried out by calculating the mean
size of necroinflammatory foci contained in 100 high power fields,
corresponding to about 4 mm
2 of liver tissue, as described [21].
Immunohistochemistry, immunofluorescence and
confocal microscopy
Immunohistochemical staining for hepatitis B core antigen
(HBcAg), HMGB-1, CC3, PCNA and Ki67 was performed as
described [16,17,36,58]. The number of CC3
+ hepatocytes was
calculated in 100 high power fields, corresponding to about 4 mm
2
of liver tissue. Immunofluorescence staining for F4/80 was
performed as described [50]. Confocal microscopy was carried
out with an Axioskop 2 plus direct microscope (Zeiss) equipped
with a Radiance 2100 three-laser confocal device (Bio-Rad).
Images were analyzed with Paint Shop Pro X (Corel).
Serum HMGB-1 ELISA
The serum concentration of HMGB-1 was measured by the use
of the mouse ELISA kit II (Shino-Test Corporation, Japan) as
previously described [59].
Statistical analysis
In all studies, values are expressed as mean 6 SD. All statistical
analyses were performed in Prism (GraphPad Software). Means
between two groups were compared by using a two-tailed t-test.
Means between three or more groups were compared by using a
one-way or two-way analysis of variance with Bonferroni’s post-
test. Kaplan–Meier survival curves were compared by using the
log-rank (Mantel–Cox) test. Differences were considered statisti-
cally significant at p,0.05.
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The GeneBank or NCBI Reference Sequence (RefSec) numbers
for the genes and proteins cited in the text are: IFN-c K00083.1
(GeneBank); CXCL9, NC_000071.5 (RefSec); CXCL10,
NC_000071.5 (RefSec); TNF-a, M11731.1 (GeneBank); IL-10,
M37897.1 (GeneBank); TGF-b M13177.1 (GeneBank); CXCL1,
NC_000071.5 (RefSec); HMGB-1, NC_000013.10 (RefSec);
MSR-1 NM_031195.2 (RefSeq); Scarb-1 NM_016741.1 (RefSeq).
Supporting Information
Figure S1 The effect of Clo-L- or GdCl3-treatments. (A)
Representative confocal micrographs of control (left panel) or
Clo-L-injected (right panel) HBV replication-competent transgenic
livers, three days after treatment. Anti-F4/80 staining in red, TO-
PRO-3 (TP3) staining of nuclei in blue. Scale bar represents
150 mm. n=3. (B) Absolute number of intrahepatic CD11c
high
DCs recovered from the mice described in (A). n=3. (C)
Frequency of blood Gr-1
high CD11b
+ PMNs and (D) Ly-6C
+
monocytes recovered from the mice described in (A). n=3. (E)
Representative confocal micrograph of HBV replication-compe-
tent transgenic livers 5 minutes after intravenous injection of red
fluorescent beads. Anti-F4/80 staining in blue. Scale bar
represents 10 mm. n=3. (F) Bead concentration in the blood of
control (NaCl) or Clo-L-treated HBV replication-competent
transgenic mice. n=6. (G) Representative confocal micrographs
of control (left panel) or GdCl3-injected (right panel) HBV
replication-competent transgenic livers, one day after treatment
cessation. Anti-F4/80 staining in red, TO-PRO-3 (TP3) staining
of nuclei in blue. Scale bar represents 150 mm. n=3. All data are
expressed as mean 6 standard deviation and are representative of
at least 3 independent experiments that gave similar results;
differences between mice treated or not with Clo-L were not
statistically significant unless otherwise indicated, * p,0.05,
** p,0.001.
(TIF)
Figure S2 Similar liver disease severity in mice administered
with either saline (NaCl) or saline-containing liposomes (NaCl-L)
prior to CTL transfer. Mean sALT activity (units/liter) measured
at the indicated time points after intravenous injection of 10
7
HBV-specific CTL in HBV replication-competent transgenic mice
that received the indicated treatment (NaCl + CTL or Clo-L +
CTL mice representing additional controls of this specific
experiment have been described in Figure 3A). n=6. Data are
expressed as mean 6 standard deviation and are representative of
at least 2 independent experiments that gave similar results; note
that no difference in sALT activity was detected between NaCl-
and NaCl-L-injected mice at all time points after CTL transfer.
(TIF)
Figure S3 Clo-L treatment does not affect sALT half-life. Mean
sALT activity (units/liter) measured at the indicated time points
after intravenous injection of liver extracts of a known ALT
content (,6000 U) in HBV replication-competent transgenic
control (white) or Clo-L-treated (black) mice. n=6. All data are
expressed as mean 6 standard deviation and are representative of
at least 3 independent experiments that gave similar results.
Differences were not statistically significant.
(TIF)
Figure S4 Clo-L treatment does not affect HBcAg clearance.
Representative immunohistochemical micrographs of HBV repli-
cation-competent transgenic livers five days after intravenous
injection of NaCl (left panel), NaCl +10
7 HBV-specific CTL
(middle panel) or Clo-L +10
7 HBV-specific CTL. HBcAg staining
in brown. Scale bar represents 150 mm.
(TIF)
Figure S5 Comparable serum levels of albumin or bilirubin in
mice treated or not with Clo-L. Mean serum levels of albumin
(A) or bilirubin (B) measured at the indicated time points after
intravenous injection of 10
7 HBV-specific CTL in HBV
replication-competent transgenic mice that received the indicated
treatment. n=6. All data are expressed as mean 6 standard
deviation and are representative of at least 3 independent
experiments that gave similar results. Differences were not
statistically significant.
(TIF)
Figure S6 a-Gr-1 and a-HMGB-1 Abs reduce blood and liver
PMNs counts. (A) Absolute number of Gr-1
high CD11b
+ PMNs in
the blood of HBV replication-competent transgenic CTL-injected
mice that received NaCl (white squares), Clo-L and irrelevant (Irr)
Abs (black triangles) or Clo-L and anti-Gr-1 antibodies (aGr-1,
black circles). n=6. (B) Absolute number of Gr-1
high CD11b
+
neutrophils (PMNs) recovered from the livers of mice that received
NaCl (white squares), Clo-L and irrelevant (Irr) Abs (black
triangles) or Clo-L and the anti-HMGB-1 Ab DPH1.1
(aHMGB-1, black circles) along with the intravenous injection of
10
7 HBV-specific CTL. (C) Representative western blots of 500 ng
(lane 1) or 100 ng (lane 2) of the recombinant Box-A fragment of
HMGB-1 (negative control) and 500 ng (lane 3) or 100 ng (lane 4)
of recombinant HMGB-1 incubated with either the a-HMGB-1
Ab DPH1.1. (top panel) or a control anti-Box-A fragment Ab
control (bottom panel). (D) Representative micrographs of mouse
embryonic fibroblasts (MEFs) derived from either wild type (wt)
mice or HMGB-1
2/2 mice that were stained by immunofluores-
cence with the a-HMGB-1 Ab DPH1.1. Scale bar represents
20 mm. (E) Transmigration of 3T3 cells toward a HMGB-1
gradient in the presence of the indicated concentrations of the a-
HMGB-1 Ab DPH1.1 was examined using a modified Boyden
chamber assay. Each bar represents the mean number of migrated
cells 6 standard deviation of triplicate samples.
(TIF)
Figure S7 The effect of whole-body irradiation on liver disease
severity. Clo-L treated and relative control HBV replication-
competent transgenic mice were subjected to whole-body
irradiation four hours prior to the transfer of 10
7 HBV-specific
CTL. (A) Frequency of blood Gr-1
high CD11b
+ polymorphonu-
clear neutrophils (PMNs) and (B) Ly-6C
+ monocytes recovered
four hours after whole-body irradiation. n=3. (C) Mean sALT
activity (units/liter) measured at the indicated time points after
CTL transfer in mice that received the indicated treatment. n=6.
(D) Kaplan-Meier survival curves of control (white) or Clo-L-
treated (black) whole-body irradiated mice described in (B). n=6.
(E) Representative micrographs of hematoxylin/eosin-stained of
Clo-L + CTL- (left), Irradiation + NaCl + CTL- (middle) or
Irradiation + Clo-L + CTL- (right) treated HBV replication-
competent transgenic livers, three days after intravenous injection
of 10
7 HBV-specific CTL. Broken line delineates necroinflamma-
tory foci. Note the abundant inflammatory infiltrate in the liver of
mice treated with Clo-L + CTL (left), as opposed to what detected
in the liver of mice treated with Irradiation + Clo-L + CTL (right).
Note also the lack of large areas of damaged hepatocytes (and
abundant inflammatory infiltrates) in irradiated mice not treated
with Clo-L. All data are expressed as mean 6 standard deviation
and are representative of at least 2 independent experiments that
gave similar results; differences between CTL-injected mice
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otherwise indicated, ** p,0.001.
(TIF)
Figure S8 The scavenger receptor ligand Poly(I) inhibits liver
phagocytosis. (A) Total RNA isolated from HBV-specific CTL,
total liver RNA or KCs were analyzed by real time qPCR for the
expression of macrophage scavenger receptor 1 (MSR-1) and
scavenger receptor class b1 (Scarb-1). Results are expressed as
arbitrary units after normalization for the housekeeping gene
GAPDH. n=6. (B) Representative confocal micrographs of HBV
replication-competent transgenic livers 5 minutes after intrave-
nous injection of Poly(U) (top panel) or Poly(I) (bottom panel).
Anti-F4/80 staining in red, TO-PRO-3 (TP3) staining of nuclei
in blue. Scale bar represents 150 mm. n=3. (C) Absolute number
of intrahepatic CD11c
high DCs, NK1.1
+ CD3
2 NK cells and
NK1.1
+ CD3
+ NKT cells recovered from the mice described in
(B). n=3. (D) Bead concentration in the blood of HBV
replication-competent transgenic mice that received the indicated
treatment. n=6. All data are expressed as mean 6 standard
deviation and are representative of at least 3 independent
experiments that gave similar results; differences between mice
treated with Poly(U) or Poly(I) were not statistically significant
unless otherwise indicated; * p,0.05.
(TIF)
Video S1 PGK-GFP 1.3.32 HBV chimeric mice in which KCs
and circulating white blood cells express GFP (green) were
subjected to liver intravital microscopy. The movie depicts
periportal liver sinusoids in a representative mouse that was
infused 15 minutes earlier with 10
8 rhodamine-labeled beads (red)
and 5 minutes earlier with 10
6 Hoechst-labeled HBV-specific
effector CD8 T cells (blue). The movie shows an example of a
virus-specific effector CD8 T cell arresting in close proximity and
transiently coming in contact with a KC. Analysis of 30 minutes
movies derived from 6 independent chimeric mice showed 30% of
visualized HBV-specific effector CD8 T cells interacting with KCs
(mean interaction time of 561 second). Scale bar represents
50 mm.
(MOV)
Video S2 HBV replication-competent transgenic mice were
injected with NaCl and 3 days later subjected to liver intravital
microscopy. The movie depicts lobular liver sinusoids in a
representative mouse that was infused 5 minutes earlier with
5610
7 CFSE-labeled HBV-specific effector CD8 T cells. Analysis
of movies derived from six independent HBV replication-
competent transgenic mice revealed a sticking fraction (defined
as the percentage of total CD8 T cells that became firmly adherent
for $30 s while passing a liver sinusoid within a 30 minutes
observation period) of 29.2%63.1%. Note that the sticking
fraction of effector CD8 T cells that were specific for an irrelevant
antigen (LCMV) and were infused into HBV replication-
competent transgenic mice was detected as less than 5% (not
shown). Scale bar represents 50 mm.
(MOV)
Video S3 HBV replication-competent transgenic mice were
injected with Clo-L and 3 days later subjected to liver intravital
microscopy. The movie depicts lobular liver sinusoids in a
representative mouse that was infused 5 minutes earlier with
5610
7 CFSE-labeled HBV-specific effector CD8 T cells (green).
Analysis of movies derived from six independent HBV replication-
competent transgenic mice revealed a sticking fraction (defined as
the percentage of total CD8 T cells that became firmly adherent
for $30 s while passing a liver sinusoid within a 30 minutes
observation period) of 27.1%61.9%. Scale bar represents 50 mm.
(MOV)
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